专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3214172B1 METHOD FOR PRODUCING REMCOMBINANT HUMAN DNASEI 有权
公开(公告)号：EP3214172B1
公开(公告)日：2019-02-13
申请号：EP15855317.2
申请日：2015-10-19
申请人： JCR Pharmaceuticals CO., LTD.
发明人： KOSHIMURA, Yuri , MATEV, Miroslav , SONODA, Hiroyuki
IPC分类号： C12N9/22

2. 发明公开

EP3315606A1 ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY PERMEATING BLOOD-BRAIN BARRIER 审中-实审
标题翻译：抗人转铁蛋白受体抗体渗透血脑屏障
公开(公告)号：EP3315606A1
公开(公告)日：2018-05-02
申请号：EP16814464.0
申请日：2016-06-24
申请人： JCR Pharmaceuticals Co., Ltd.
发明人： SONODA, Hiroyuki , TAKAHASHI, Kenichi
IPC分类号： C12N15/09 , A61K39/395 , A61K45/00 , A61P9/10 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P31/04 , A61P31/12 , A61P35/00 , C07K14/475 , C07K16/18 , C07K16/28 , C07K16/46 , C07K19/00
CPC分类号： C07K16/28 , A61K39/395 , A61K45/00 , A61K2039/505 , A61P25/00 , C07K14/475 , C07K14/505 , C07K14/7151 , C07K16/18 , C07K16/46 , C07K19/00 , C07K2317/24 , C07K2317/92 , C07K2319/30 , C12N5/10 , C12N9/10 , C12N9/14 , C12N9/16 , C12N9/24 , C12N9/2402 , C12N9/48 , C12N9/64 , C12N15/09 , C12N15/113 , C12Y301/02 , C12Y302/01076 , C12Y304/14009 , C12Y310/01001
摘要： Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.
摘要翻译：公开了一种将具有生理或药理活性并且不能通过血脑屏障的化合物转化为允许它们穿过血脑屏障的形式以及由此转化的化合物的手段。该手段是抗人转铁蛋白受体抗体，并且转化的化合物是生理活性蛋白质或药理活性低分子量化合物与抗人转铁蛋白受体抗体之间的分子缀合物。

3. 发明授权

EP2206777B1 METHOD FOR PRODUCING AMINOPEPTIDASE 失效
标题翻译：用于生产氨肽酶
公开(公告)号：EP2206777B1
公开(公告)日：2014-01-15
申请号：EP08844506.9
申请日：2008-10-25
申请人： JCR Pharmaceuticals CO., LTD.
发明人： SONODA, Hiroyuki , DAIMON, Katsuya , SUGIMURA, Atsushi
IPC分类号： C12N15/09 , C12N1/21 , C12N9/52
CPC分类号： C12N9/48 , C12N9/52 , C12P13/24 , C12P21/06

4. 发明公开

EP2206777A1 METHOD FOR PRODUCING AMINOPEPTIDASE 失效
标题翻译： VERFAHREN ZUR HERSTELLUNG VON AMINOPEPTIDASE
公开(公告)号：EP2206777A1
公开(公告)日：2010-07-14
申请号：EP08844506.9
申请日：2008-10-25
申请人： JCR Pharmaceuticals CO., LTD.
发明人： SONODA, Hiroyuki , DAIMON, Katsuya , SUGIMURA, Atsushi
IPC分类号： C12N15/09 , C12N1/21 , C12N9/52
CPC分类号： C12N9/48 , C12N9/52 , C12P13/24 , C12P21/06
摘要： Disclosed is an efficient method for production of aminopeptidase. The method comprises either transforming host bacteria with an aminopeptidase gene and with a neutral protease gene, or transforming some part of host bacteria with an aminopeptidase gene while transforming the other part of the host bacteria with a neutral protease gene, culturing in a medium the hose bacteria transformed with the aminopeptidase gene and with the neutral protease gene, or culturing a mixture of the host bacteria transformed with the aminopeptidase gene and the host bacteria transformed with the neutral protease gene, to let both the aminopeptidase and the neutral protease be expressed, and collecting the aminopeptidase thus produced from the culture mixture.
摘要翻译：公开了生产氨基肽酶的有效方法。该方法包括用氨基肽酶基因和中性蛋白酶基因转化宿主细菌，或用氨基肽酶基因转化宿主细菌的一部分，同时用中性蛋白酶基因转化宿主细菌的另一部分，在培养基中培养软管用氨基肽酶基因和中性蛋白酶基因转化的细菌，或培养与氨基肽酶基因转化的宿主细菌和用中性蛋白酶基因转化的宿主细菌的混合物，使氨基肽酶和中性蛋白酶都表达，以及收集由培养混合物制得的氨基肽酶。

5. 发明公开

EP3505538A1 METHOD FOR PRODUCING ANTIBODY FUSION PROTEIN 有权
公开(公告)号：EP3505538A1
公开(公告)日：2019-07-03
申请号：EP17843719.0
申请日：2017-08-25
申请人： JCR Pharmaceuticals Co., Ltd.
发明人： KOSHIMURA, Yuri , SONODA, Hiroyuki , MATEV, Miroslav , KAKIMOTO, Shinji , FUKUI, Tsuyoshi , HATANO, Yukichi
IPC分类号： C07K19/00 , A61K39/395 , C07K16/28 , C12N9/16 , C12N5/10 , C12N15/09
摘要： Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.

6. 发明公开

EP3450557A1 NOVEL ANTI-TRANSFERRIN RECEPTOR ANTIBODY THAT PASSES THROUGH BLOOD-BRAIN BARRIER 审中-公开
公开(公告)号：EP3450557A1
公开(公告)日：2019-03-06
申请号：EP18199592.9
申请日：2014-12-24
申请人： JCR Pharmaceuticals Co., Ltd.
发明人： SONODA, Hiroyuki , MORIMOTO, Hideto , KOSHIMURA, Yuri , KINOSHITA, Masafumi , TAKAGI, Haruna , YOSHII, Yoshiko
IPC分类号： C12N15/09 , C07K16/18 , C07K19/00 , C12N5/071
摘要： Disclosed are novel anti transferrin receptor antibody that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C- terminal side.

7. 发明公开

EP3088518A1 NOVEL ANTI-TRANSFERRIN RECEPTOR ANTIBODY THAT PASSES THROUGH BLOOD-BRAIN BARRIER 审中-公开
标题翻译： DURCH DIE BLUT-HIRN-SCHRANKE PASSIERENDER，NEUARTIGER ANTI-TRANSFERRIN-REZEPTORANTIKÖRPER
公开(公告)号：EP3088518A1
公开(公告)日：2016-11-02
申请号：EP14873852.9
申请日：2014-12-24
申请人： JCR Pharmaceuticals Co., Ltd.
发明人： SONODA, Hiroyuki , MORIMOTO, Hideto , KOSHIMURA, Yuri , KINOSHITA, Masafumi , TAKAGI, Haruna , YOSHII, Yoshiko
IPC分类号： C12N15/09 , C07K16/18 , C07K19/00 , C12N5/071
CPC分类号： C07K16/2881 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C12N9/16 , C12Y301/06013
摘要： Disclosed are novel anti transferrin receptor antibody that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C- terminal side.
摘要翻译：公开了可以通过血脑屏障的新型抗转铁蛋白受体抗体，包含必需在中枢神经系统和抗体中起作用的蛋白质的融合蛋白及其制备方法。融合蛋白包含识别选自SEQ ID NO：1,2和3的氨基酸序列的抗人转铁蛋白受体抗体的氨基酸序列，以及结合在其上的其它蛋白质，终端侧。

8. 发明公开

EP4455290A1 FUSION PROTEIN OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY AND BIOACTIVE PROTEIN FOR SAFE GENE THERAPY 失效
公开(公告)号：EP4455290A1
公开(公告)日：2024-10-30
申请号：EP22916101.3
申请日：2022-12-27
申请人： JCR Pharmaceuticals Co., Ltd.
发明人： KINOSHITA, Masafumi , TAKAGI, Haruna , IIZUKA, Shunsuke , OHTSUKI, Kota , SONODA, Hiroyuki
IPC分类号： C12N15/62 , A01K67/027 , C12N5/0735 , C12N5/074 , C12N5/0775 , C12N5/0789 , C12N5/0797 , C12N5/10 , C12N7/01 , C12N15/12 , C12N15/13 , C12N15/63
CPC分类号： C07K14/435 , C07K16/00 , C12N5/06 , C12N5/10 , C12N7/00 , C12N15/62 , C12N15/63 , A01K67/027
摘要： An object of the present invention is to provide a nucleic acid molecule or a viral virion containing the nucleic acid molecule, the nucleic acid molecule having integrated therein a gene encoding a fusion protein of an anti-transferrin receptor antibody and a physiologically active protein, the fusion protein having an adjusted binding activity to TfR, and being capable of reducing a side reaction such as an anemia symptom caused by binding of the anti-TfR antibody to the transferrin receptor, for example, when the gene encoding the fusion protein of the anti-TfR antibody and the physiologically active protein is used in gene therapy.

9. 发明公开

EP4265715A1 NUCLEIC ACID MOLECULE CONTAINING INCORPORATED GENE ENCODING FUSED PROTEIN OF LIGAND AND PROTEIN HAVING PHYSIOLOGICAL ACTIVITY 审中-实审
公开(公告)号：EP4265715A1
公开(公告)日：2023-10-25
申请号：EP22739365.9
申请日：2022-01-11
申请人： JCR Pharmaceuticals Co., Ltd.
发明人： KINOSHITA, Masafumi , IIZUKA, Shunsuke , IMAKIIRE, Atsushi , TAKAGI, Haruna , SONODA, Hiroyuki
IPC分类号： C12N5/0735 , C12N5/074 , C12N5/0775 , C12N5/0789 , C12N5/0797 , C12N5/10 , C12N7/01 , C12N15/113 , C12N15/12 , C12N15/13 , C12N15/34 , C12N15/40 , C12N15/51 , C12N15/62 , C12N15/63 , A01K67/027
摘要： The invention provides a nucleic acid molecule comprising a gene encoding a fusion protein of a ligand and a protein having physiological activity, to be used for expressing the fusion protein in cells, tissue or the body. The invention further provides a nucleic acid molecule comprising the fusion protein-encoding gene, which is in the form of a plasmid, in a form encapsulated in a recombinant virus virion, or a form encapsulated in liposomes or lipid nanoparticles. The invention further relates to the use of a medicine which is a nucleic acid molecule comprising the fusion protein-encoding gene.

10. 发明公开

EP3315515A1 FUSION PROTEIN CONTAINING BDNF 审中-实审
标题翻译：含有BDNF的融合蛋白
公开(公告)号：EP3315515A1
公开(公告)日：2018-05-02
申请号：EP16814465.7
申请日：2016-06-24
申请人： JCR Pharmaceuticals Co., Ltd.
发明人： SONODA, Hiroyuki , TAKAHASHI, Kenichi
IPC分类号： C07K19/00 , A61K38/22 , A61K39/395 , A61P9/10 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P27/02 , A61P43/00 , C07K14/48 , C07K16/28 , C12N5/10 , C12N15/09
CPC分类号： C07K16/2881 , A61K38/22 , A61K39/395 , A61K2039/505 , C07K14/475 , C07K14/48 , C07K16/28 , C07K19/00 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/74 , C12N5/10 , C12N15/09
摘要： Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.
摘要翻译：公开了含有脑源性神经营养因子（BDNF）的融合蛋白。该融合蛋白是BDNF与特定范围的人抗转铁蛋白受体抗体的融合蛋白，其使得BDNF被施用到能够通过血脑屏障的血液中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式